Other Events ·
EyePoint, Inc. entered into a settlement agreement with the U.S. Department of Justice and other agencies to settle…
EYPTEyePoint, Inc.
EyePoint, Inc. entered into a settlement agreement with the U.S. Department of Justice and other agencies to settle potential civil False Claims Act violations related to DEXYCU sales and marketing practices between 2019 and 2023. The company will pay a settlement amount of $4,678,981.86 plus 4.25% interest, along with $166,500 in attorney's fees. Additionally, the company entered into a five-year Corporate Integrity Agreement with OIG-HHS to maintain compliance oversight. EyePoint, Inc. is a pharmaceutical company that commercializes healthcare products.